Eli Lilly's retatrutide cut sleep apnea symptoms in two trials

Two trials of Eli Lilly's retatrutide showed significant reductions in apnea and hypopnea episodes versus placebo in people with obesity and obstructive sleep apnea. The studies involved about 700 participants, some with type 2 diabetes, and were published in the New England Journal of Medicine.

• About 700 participants across two retatrutide sleep apnea trials
• Over half in one trial reached remission or mild apnea
• Many participants no longer needed a CPAP machine
• Effect was smaller but significant in people with type 2 diabetes